MedTrace Logo

Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia

NCT00677859 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-01-05

No results posted yet for this study

Summary

The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.

Conditions

Interventions

BIOLOGICAL

MultiStem®

Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.

BIOLOGICAL

MultiStem®

Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®

Sponsors & Collaborators

  • Cato Research

    collaborator INDUSTRY

  • Healios K.K.

    lead INDUSTRY

Principal Investigators

  • Richard Maziarz, MD · Oregon Health and Science University

  • Steven Devine, MD · Ohio State University

  • Hillard Lazarus, MD · Case Western Reserve University

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • United States
  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00677859 on ClinicalTrials.gov